Tachi Yamada, 60, is retiring this summer from one of the biggest jobs in the pharmaceutical industry to take on an even bigger assignment where he will have a $28 billion budget to tackle killer diseases from Aids to dipthheria as well as whooping cough, measles, polio and yellow fever.
As chairman of Glaxo SmithKline’s research and development operations, Yamada is credited with turning the company with the worst pipeline of news drugs into one with the best. He is now leaving to run the global health programme of the Bill and Melinda Gates Foundation, the world’s largest charitable organization.
Stepping into his place at GSK is Dr. Moncef Slaoui, a senior colleagues who has been with the company 17 years, is a recognised expert on vaccines, has dual Belgian and Morocco nationality and speaks fluent English, French and Arabic.
According to observers, these changes point to a top management reshuffle in the foreseeable future involving a successor to Dr. Jean-Pierre Garnier, the company’s Chief Executive Officer.
Thanks for reading Big Business